Versitech, Inc.

Athenex Hk Innovative Limited

Nansha Biologics (hong Kong) Limited

Athenex, Inc.

Avalon Photonics (hk) Limited

Health Hope Pharma Ltd

Atnx Spv, LLC

Avalon Spinecare (hk) Limited

Nansha Biologies (hong Kong) Limited

Emv Enhance (hk) Limited

Nansha Biologies (hk) Limited

Athenex R&d. LLC

Avalon Polytom (hk) Limited

Avalon Polymills (hk) Limited

Johnson Yiu-Nam Lau

Qui-Lim Choo

Kwok Yung Yuen

Min-Fun Rudolf Kwan

E Douglas Kramer

Kuo-Ming Yu

Manson Fok

David Lawrence Cutler

Fan Ngai Hung

Kai Wang Kelvin To

Michael P Smolinski

Fuk Woo Jasper Chan

Wing Kai Chan

Jinxia Zhang

Ming Tsung Lee

Shuofeng Yuan

Kwok-Yung Yuen

Sameer Urgaonkar

Murray John Cutler

Sai Keung Chow

Chun Lung Choi

Denise S B Chan

Chi Yeung Mang

Weng Li Yoon

Chun Ho Wong

Jane Fang

Honglin Chen

Chi Wai Kan

Pui Wang

Min Zheng

Ka Fu Yung

Kim Hung Lam

Yuk Lun Tsang

Nader N Nasief Abdel Sayed

Lut Hey Chu

Ahmed M Said

Laura Beth Pitzonka

Krista Elizabeth Belko

Alissa Rae Verone-Boyle

Chun-Ho Wong

Yahao Bu

Philip Man Lung Yeung

Hin Chu

Pui Shi Pang

Denise So Bik Chan

Jiachi Chiou

Wai Han Lam

Yun Chung Leung

Yuk-Keung Yeung

Raymond Hung To Yeung

Wing Yan Lau

Jie Zhou

Denise Sb Chan

Denise SB Chan

Compositions and methods are described that provide cellulosic and non-cellulosic fabrics with durable antimicrobial properties. Application of a coating that includes polyhexamethylene biguanide, polyethylene glycol, and a binder to a fabric followed by drying and curing was found to provide antimicrobial properties that are retained through over 100 washings under aggressive hospital washing conditions. In addition, tactile properties and tear resistance of the treated fabrics are maintained or improved.

Durable antimicrobial treatment of textile for use in healthcare environment

HM30181 (shown below) can be used to improve absorption of cancer chemotherapy drugs, such as paclitaxel. Herein are described various polymorphisms of HM30181, in particular polymorphisms B, D, E, F, G, H, I, J, K, L, and M as well as their physical properties and methods for their preparation and characterization.

Polymorphisms of HM30181 mesylate

AM580 and structurally related compounds have been found to be useful in treating infection by a wide range of RNA and DNA viruses, and also in reducing associated inflammation. This activity is independent of RAR-α signaling, and is not a result of activation of the hosts innate immune response. Broad antiviral activity of AM580 and structurally related compounds is a due to modulation of lipogenesis so as to correct disregulation of this pathway in virus-infected cells, via inhibition of nSREPBP.

Compositions and methods for broad-spectrum antiviral therapy

Miltefosine is utilized to enhance immune response to vaccination, for example an influenza and/or coronavirus vaccination. The inventive subject matter also provides compositions and methods for enhancing viral yield in cultured cells, by application of a cannabinoid receptor agonist (such as methanandamide) to such cells. Such enhanced viral yield can be used to enhance virus production for purposes of vaccine formulation and/or to improve sensitivity of cell-based virus assays.

Compositions and methods for enhancing immune response to vaccination and improving vaccine production

Devices and methods that utilize an occlusive dressing in combination with a topical pharmaceutical agent to enhance vaccine efficacy are described. The occlusive dressing delivers a defined dose of a topical pharmaceutical agent that enhances immune system reactivity to a vaccine to the site of vaccination, and provides a barrier that maintains a layer of the topical pharmaceutical agent on the skin for a desired period to time while also providing a port through which an immunizing composition can be administered. In some embodiments the occlusive dressing includes a wound dressing for covering the injection site following vaccination.

Devices and methods for enhancing immunogenicity to intradermal vaccination

A pharmaceutical composition comprises a taxane (e.g., paclitaxel, docetaxel, cabazitaxel, larotaxel, ortataxel, and/or tesetaxel) in a mixture of first and second surfactants. The absorption of the taxane is increased from the pharmaceutical composition is greater than the sum of the absorption of docetaxel from either the first or the second surfactant. The increase in absorption is especially enhanced when the ratio of the first surfactant to the second surfactant in the pharmaceutical composition is between 60:40 and 85:15 by weight, and the total surfactant weight does not exceed 98% of the total weight. Polysorbate 80, polysorbate 20, and caprylocaproyl polyoxylglycerides serve as suitable first surfactants, and polysorbate 80 or polyethyoxylated castor oil serve as suitable second surfactants. The stability of the pharmaceutical composition may be enhanced by further including a stabilizer (e.g., citric acid and/or ascorbic acid).

Oral taxane compositions and methods

Methods are provided for producing a PEGylated interleukin 11 (IL-11) by treating a recombinant IL-11 PEGylated with an equimolar to low molar excess of PEG carrying an amine-reactive group to achieve a highly pure monoconjugate preparation, which provides improved half-life in serum while having desirable therapeutic activity and presenting fewer side-effects. Most preferably, the IL-11 is an N-terminally truncated human or humanized IL-11 and has a 20 Kd or 40 Kd branched PEG moiety, Y- or comb-shaped in particular, coupled to the N-terminal amino group. Such compounds are characterized by substantially increased stability in serum and sustained biological activity while exhibiting significantly reduced plasma expansion.

Methods of preparing a pegylated human IL-11 composition

Compositions and methods for the preparation of high purity arginase and high efficiency preparation of monosubstituted polyethylene glycol conjugation of arginase are provided, as are methods for using arginase in combination with asparaginase to inhibit cancer cells. High purity arginase is provided by applying an initial high temperature precipitation step, followed by ion exchange to provide arginase at a purity of 90% or greater. Conjugation with either linear or branched polyethylene glycol is performed using a maleimide-derivatized polyethylene glycol at low molar excess relative to arginase and at reduced temperature. Such polyethylene glycol-derivatized arginase is useful in combination with asparaginase in inhibiting the growth of cancer cells, particularly cells that have low endogenous asparaginase expression.

Compositions and methods for amino acid depletion therapy

Enteroviruses, such as EV-A71, have been found to utilize hWARS as a cell surface receptor, with expression ofhWARS rendering cells susceptible to enteroviral infection. Reduction in hWARS cell surface activity reduces susceptibility to enteroviral infection and provides a mode for treatment or prevention of enteroviral infection and its sequelae. Similarly, expression of hWARS in cultured cells and animal models provides models for understanding enteroviral disease mechanisms and the development of vaccines and/or pharmaceuticals for preventing or treating enteroviral disease.

Compositions and methods for treatment of enterovirus infection

Compositions and methods are provided that are effective in treating skin hyperproliferative disorders. These include a topical pharmaceutical preparation that includes a compound that has two or more of a SRC-kinase inhibiting activity, a tubulin polymerization inhibiting activity, an activity that arrests the cell cycle at G2/M, and an activity that induces apoptosis. The compound KX01 is provided as an example of such a compound. The topical pharmaceutical preparation further includes a vitamin D derivative or a retinoid, where the combination provides a synergistic effect. Use of the topical pharmaceutical preparation can be combined with exposure to blue, UVA, or UVB light, which provides a synergistic effect.

Compositions and methods for treating hyperproliferative skin disorders

The present disclosure provides pharmaceutical combinations of orally administered irinotecan and a P-gp inhibitor. The pharmaceutical combinations are suitable for the treatment of cancer in a subject and for reducing or preventing toxicity, hypersensitivity-type infusion reactions, and other negative outcomes resulting from or associated with intravenously administered irinotecan (e.g., Camptosar&#xae;) therapy in a subject suffering from cancer.

Therapeutic combinations of orally administered irinotecan and a p-gp inhibitor for the treatment of cancer

The present disclosure relates to compounds of Formula (IA) and to their prodrugs, pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for the treatment of disorders in which P-glycoprotein and/or cytochrome P450 (e.g. CYP3A4) is modulated (e.g., cancers which have developed multi-drug resistance).

Acetamido-phenyltetrazole derivatives and methods of using the same

HM30181 (shown below) can be used to improve absorption of cancer chemotherapy drugs, such as paclitaxel. Herein are described various polymorphisms of HM30181, in particular polymorphism C, as well as their physical properties and methods for their preparation and characterization.

Recombinant interleukin-11 (rhIL-11) is expressed in yeast, then isolated from aerobic fermentation media by precipitation, solubilization of the precipitate in the presence of a denaturant, and renaturation of the solubilized protein. Renatured rhIL-11 is further purified by cation exchange and hydrophobic interaction chromatography to provide a highly purified rhIL-11 with high biological activity and low rhIL-11 dimer and oxidized rhIL-11 content.

Systems and methods for production of recombinant IL-11 in yeast

The application pertains to methods of treating and/or preventing actinic keratosis, comprising administering a therapeutically effective amount of KX-01, to a subject in need thereof.

Methods of treating and/or preventing actinic keratosis

Growing community of inventors

Houston, TX, United States of America

Johnson Yiu-Nam Lau